Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study
- 3 April 2014
- journal article
- research article
- Published by Wiley in Pediatric Diabetes
- Vol. 16 (3) , 196-203
Abstract
Background Insulin resistance increases during adolescence in those with type 1 diabetes mellitus (T1DM), complicating glycemic control and potentially increasing cardiovascular disease (CVD) risk. Metformin, typically used in type 2 diabetes mellitus (T2DM), is a possible adjunct therapy in T1DM to help improve glycemic control and insulin sensitivity. Objective We hypothesized that metformin would improve metabolic parameters in adolescents with T1DM. Design, setting, and participants This randomized, double‐blinded, placebo‐controlled trial included 74 pubertal adolescents (ages: 13–20 yr) with T1DM. Participants were randomized to receive either metformin or placebo for 6 months. Glycated hemoglobin (HbA1c), insulin dose, waist circumference, body mass index (BMI), and blood pressure were measured at baseline, 3 and 6 months, with fasting lipids measured at baseline and 6 months. Results Total daily insulin dose, BMI z‐score and waist circumference significantly decreased at 3 and 6 months compared to baseline within the metformin group, even among normal‐weight participants. In the placebo group, total insulin dose and systolic blood pressure increased significantly at 3 months and total insulin dose increased significantly at 6 months. No significant change was observed in HbA1c at any time point between metformin and placebo groups or within either group. Conclusions Low‐dose metformin likely improves BMI as well as insulin sensitivity in T1DM adolescents, as indicated by a decrease in total daily insulin dose. The decrease in waist circumference indicates that fat distribution is also likely impacted by metformin in T1DM. Further studies with higher metformin doses and more detailed measurements are needed to confirm these results, their underlying mechanisms, and potential impact on CVD in T1DM youth.Keywords
Funding Information
- The American Diabetes Association Research Foundation (7-11-CD-08)
- Juvenile Diabetes Research Foundation International (11-2010-343)
This publication has 28 references indexed in Scilit:
- Insulin Resistance in Adolescents with Type 1 Diabetes and Its Relationship to Cardiovascular FunctionThe Journal of Clinical Endocrinology & Metabolism, 2010
- The use of metformin in type 1 diabetes: a systematic review of efficacyDiabetologia, 2010
- Insulin Resistance in Adolescents with Type 2 Diabetes Is Associated with Impaired Exercise CapacityThe Journal of Clinical Endocrinology & Metabolism, 2009
- Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivityEuropean Journal of Endocrinology, 2003
- Changing Prevalence of Overweight Children and Adolescents at Onset of Insulin-Treated DiabetesDiabetes Care, 2003
- Metformin as an Adjunct Therapy in Adolescents With Type 1 Diabetes and Insulin ResistanceDiabetes Care, 2003
- Metformin Adjunctive Therapy with Insulin Improves Glycemic Control in Patients with Type 1 Diabetes Mellitus: A Pilot StudyJournal of Pediatric Endocrinology and Metabolism, 2002
- [Metformin in the treatment of type 1 diabetics--a placebo controlled study].2001
- The Antihyperglycaemic Effect of MetforminDrugs, 1999
- Insulin Resistance is a Prominent Feature of Insulin-dependent DiabetesDiabetes, 1982